Clinical pediatrics · 2026
Clinical Features and Outcome of Patients With Juvenile Spondyloarthropathy in a Tertiary Hospital in the Philippines.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garcia Maria Catherine Joyce D, Bernal Christine B, Collante Ma Theresa M
Аннотация
OBJECTIVE: To describe the clinical presentation at diagnosis and identify risk factors affecting outcomes in patients with juvenile spondyloarthropathy (JSpA).
METHODS: This retrospective cohort study reviewed records of patients ≤18 years old diagnosed with JSpA (2008-2023) at a pediatric rheumatology clinic, with at least 2 follow-up visits. Remission was defined as (1) on medication (inactive disease ≥6 months) or (2) off medication (inactive disease ≥12 months).
RESULTS: Eighty-eight patients were included; 90.9% were male. The mean age of onset was 12.6 years. Peripheral arthritis (77.3%) and enthesitis (39.8%) were common. Sacroiliitis was found in 56.8% at diagnosis. Risk factors associated with sacroiliitis included peripheral arthritis and enthesitis, polyarticular, and hip involvement. Golimumab and etanercept were anti-tumor necrosis factor (TNF) agents frequently used. Clinical remission on and off medication occurred in 33% and 10.2%, respectively.
CONCLUSION: The JSpA in this cohort demonstrated substantial disease burden, with frequent axial and peripheral involvement. Although 43.2% of patients achieved clinical remission, sustained remission off medication was observed in only 10.2%, reflecting the chronic disease course. Early diagnosis and optimized treatment strategies remain essential to improve outcomes.
METHODS: This retrospective cohort study reviewed records of patients ≤18 years old diagnosed with JSpA (2008-2023) at a pediatric rheumatology clinic, with at least 2 follow-up visits. Remission was defined as (1) on medication (inactive disease ≥6 months) or (2) off medication (inactive disease ≥12 months).
RESULTS: Eighty-eight patients were included; 90.9% were male. The mean age of onset was 12.6 years. Peripheral arthritis (77.3%) and enthesitis (39.8%) were common. Sacroiliitis was found in 56.8% at diagnosis. Risk factors associated with sacroiliitis included peripheral arthritis and enthesitis, polyarticular, and hip involvement. Golimumab and etanercept were anti-tumor necrosis factor (TNF) agents frequently used. Clinical remission on and off medication occurred in 33% and 10.2%, respectively.
CONCLUSION: The JSpA in this cohort demonstrated substantial disease burden, with frequent axial and peripheral involvement. Although 43.2% of patients achieved clinical remission, sustained remission off medication was observed in only 10.2%, reflecting the chronic disease course. Early diagnosis and optimized treatment strategies remain essential to improve outcomes.